TET2 is another epigenetic modifier which is frequently mutated in hematological malignancies, including chronic myelomonocytic leukemia (CMML), MDS/myeloproliferative neoplasms (MPNs), AML, and T- or B-cell lymphoma [64,65,66,67]. Here, TET2 is linked to acute myeloid leukemia.